IMAB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. While IMAB has a great health rating, there are worries on its profitability. IMAB is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

2. Health

3. Growth

4. Valuation

5. Dividend

1. Profitability

1.1 Basic Checks

In the past year IMAB has reported negative net income.
In the past 5 years IMAB reported 4 times negative net income.
In the past 5 years IMAB reported 4 times negative operating cash flow.

1.2 Ratios

IMAB's Return On Assets of -18.22% is fine compared to the rest of the industry. IMAB outperforms 77.61% of its industry peers.
IMAB's Return On Equity of -19.14% is amongst the best of the industry. IMAB outperforms 84.70% of its industry peers.

		Industry Rank	Sector Rank
ROA	-18.22%
ROE	-19.14%
ROIC	N/A

ROA(3y)-42.75%

ROA(5y)-32.49%

ROE(3y)-60.9%

ROE(5y)-45.09%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IMAB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMAB has been increased compared to 5 years ago.
There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 23.66 indicates that IMAB is not in any danger for bankruptcy at the moment.
IMAB's Altman-Z score of 23.66 is amongst the best of the industry. IMAB outperforms 91.60% of its industry peers.
There is no outstanding debt for IMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	23.66

ROIC/WACCN/A

WACC8.67%

2.3 Liquidity

A Current Ratio of 22.86 indicates that IMAB has no problem at all paying its short term obligations.
The Current ratio of IMAB (22.86) is better than 95.90% of its industry peers.
IMAB has a Quick Ratio of 22.86. This indicates that IMAB is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of IMAB (22.86) is better than 95.90% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	22.86
Quick Ratio	22.86

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.81%, which is quite impressive.
Looking at the last year, IMAB shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)89.81%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%85.65%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.68% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y89.8%

EPS Next 2Y29.17%

EPS Next 3Y14.99%

EPS Next 5Y9.68%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMAB. No positive earnings are expected for the next year.